Hjem › B-celle lymfom › Florida
B-celle lymfom kliniske forsøg i Florida
15 studier for B-celle lymfom søger deltagere på steder i Florida.
Byer i Florida
Officiel studietekst (engelsk)
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- Memorial Cancer Institute, Memorial Healthcare System, Pembroke Pines
- Cleveland Clinic Florida, Weston
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT06742996A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
- University of California Miami, Sylvester Comprehensive Cancer Center, Miami
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT07439653Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
- Moffitt Cancer Center, Tampa
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT06350318Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
- Research Site, Tampa
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 11. sep. 2026 · NCT06526793A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
- Mayo Clinic Jacksonville, Jacksonville
- Moffitt Cancer Center, Tampa
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 11. sep. 2026 · NCT06634589A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
- Clinical Trial Site, Miami
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 4. sep. 2026 · NCT06393738A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Research Site, Jacksonville
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 28. aug. 2026 · NCT07123454Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
- University of Miami, Coral Gables
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 28. aug. 2026 · NCT07520006A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Florida Cancer Specialists, Fort Myers
- Cancer Specialists of North Florida -St Augustine, Saint Augustine
- Florida Cancer Specialists East, West Palm Beach
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 17. aug. 2026 · NCT05254743A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Mayo Clinic Florida, Jacksonville
- AdventHealth, Orlando
- Moffitt Cancer Center, Tampa
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 4. aug. 2026 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- Baptist Health Miami Cancer Institute, Miami
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 13. jul. 2026 · NCT04792489A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
- Florida Cancer Specialists, Sarasota
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 16. jun. 2026 · NCT05463263The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- ASCLEPES Research Centers, Weeki Wachee
RekruttererFase 1/2
Alder 12 til 95 · Alle køn · Opdateret 15. apr. 2026 · NCT04329728B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
- Mayo Clinic in Florida, Jacksonville
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 13. feb. 2026 · NCT06191887Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- University of Miami, Miami
RekruttererFase 1
Alder 1 til 21 · Alle køn · Opdateret 6. dec. 2024 · NCT05476770Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.